Skip to content
Open access

Chemoimmunotherapy‐associated CD20 (MS4A1) resistance mutations in Waldenström macroglobulinemia: Epitope disruption independent of expression with implications for CD20‐directed cellular therapies

Sep 2026 · HemaSphere · Vol 10 · 0 citations · 20 references
Medicine

TL;DR

CD20, encoded by MS4A1 , is one of the earliest and most extensively used immunotherapeutic targets in B ‐ cell malignancies and the mechanisms underlying resistance remain poorly understood.

Abstract

CD20, encoded by MS4A1 , is one of the earliest and most extensively used immunotherapeutic targets in B ‐ cell malignancies. In Walden-ström macroglobulinemia (WM), rituximab administered alone or with chemotherapy or BTK inhibitors is a mainstay of frontline therapy. 1 Acquired resistance to rituximab is common, though the mechanisms underlying resistance remain poorly understood. This knowledge gap is particularly relevant as novel CD20 therapies (e

Read PDF

Similar papers

Open access Nov 2026

CD20-directed Autologous CAR T-cell Therapy for Waldenström Macroglobulinemia.

No chimeric antigen receptor therapy (CAR-T) is currently approved for WM. This study assessed safety and efficacy of CD20-targeted CAR-T in BTKi-refractory, heavily pre-treated WM patients. With a CR/VGPR rate of 80%, this treatment should be evaluated in larger trials. ClinicalTrials.gov number NCT03277729.

M. Shadman, M. Redman, Sang-Yun Lee et al. · 0 citations
Open access Oct 2026

EZH2 mutation status predicts inferior outcomes after bendamustine‐based immunochemotherapy in frontline follicular lymphoma: A GELTAMO multicenter validation study

Follicular lymphoma is the most common indolent lymphoma and next ‐ generation sequencing (NGS) studies have identified recurrent mutations in chromatin ‐ modifying genes ( KMT2D, CREBBP, and EZH2 ).

C. Martínez-Laperche, Pilar Lancho-Lavilla, Antonio Gutiérrez et al. · 0 citations
Oct 2026

Iberdomide (Zenbexus) for multiple myeloma.

Iberdomide (Zenbexus – BMS), an oral first-in-class cereblon-modulating protein degrader, has received accelerated approval from the FDA for use in combination with the CD38-directed cytolytic antibody daratumumab (Darzalex Faspro) and dexamethasone for treatment of multiple myeloma in adults who received at least one...

Unknown authors · 0 citations
Review Open access Nov 2026

Hannibal ante portas: B7-H3-directed therapies at the gates of precision oncology.

Precision oncology has revolutionized cancer treatment, improving outcomes and extending survival even in aggressive cancers like small-cell lung cancer. Molecularly targeted therapies and immune checkpoint inhibitors (e.g., PD-1/PD-L1) are now standard. Recently, the immune checkpoint regulator B7-H3 (CD276) has emerg...

Krešimir Tomić, S. Vranić · 0 citations
Open access Oct 2026

Anti‐CD20 Drugs and Natalizumab Confer Equal Protection Against Progression Independent of Relapse Activity (PIRA) in People With Multiple Sclerosis

Highly effective (HE) disease‐modifying therapies (DMTs) reduce relapse‐associated worsening (RAW) and progression independent of relapse activity (PIRA). Natalizumab (NTZ) and anti‐CD20 agents show similar efficacy on relapse suppression, but long‐term comparative data on PIRA are limited. We aimed to compare PIRA acc...

L. Palazzo, F. Clarelli, Michele Surano et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.